发明公开
- 专利标题： CANCER IMMUNOTHERAPHY ADJUVANT
-
申请号： EP20798403.0申请日： 2020-04-23
-
公开(公告)号： EP3922251A1公开(公告)日： 2021-12-15
- 发明人: KWON, Young-Guen , ZHANG, Haiying , PARK, Songyi , NOH, Minyoung , KIM, Yeomyeong , KIM, Myung-Hwa , AHN, Koo Hyeon , PYO, Jung-In
- 申请人： Industry-Academic Cooperation Foundation, Yonsei University , CURACLE Co., Ltd.
- 申请人地址： KR Seoul 03722 1FL. Yonsei University Engineering Research Park 50 Yonsei-ro Seodaemun-gu; KR Seongnam-si, Gyeonggi-do 13449 No.608-No.611, 54, Changeop-ro Sujeong-gu
- 代理机构： EP&C
- 优先权： KR20190049990 20190429
- 国际公布： WO2020222461 20201105
- 主分类号： A61K31/56
- IPC分类号： A61K31/56 ; A61K31/704 ; A61K45/06 ; A61P35/00
摘要：
The present invention relates to a cancer immunotherapy adjuvant, wherein the adjuvant, when administered in combination with a cancer immunotherapy agent, activates the function of immune factors without causing in vivo side effects, to exhibit the effect of enhancing the kit for anticancer effect of the cancer immunotherapy agent, and thus can be effectively used as a cancer immunotherapy adjuvant.
信息查询
